*Visceral leishmaniasis

... (VL), also known as kala-azar, black fever, and Dumdum fever, is the most severe form of leishmaniasis ... post kala-azar dermal leishmaniasis. Brahmachari's cure for visceral leishmaniasis was the urea salt of para-amino-phenyl ... When people develop visceral leishmaniasis, the most typical symptoms are fever and the enlargement of the spleen, with ... Visceral Leishmaniasis/kala-azar samples from India revealed the presence of not only the primary causative protozoan parasite ...

*Lutzomyia

Similar increases in risk factors are also driving higher rates of visceral leishmaniasis in north-eastern Brazil. Increased ... Of the more than 350 Lutzomyia species identified, less than 10% are known or suspected to transmit leishmaniasis to humans. ... In southern Brazil, for example, levels of cutaneous leishmaniasis are increasing as a result of the adaptation of three, ... Grimaldi, G. & Tesh, R. B. (1993). "Leishmaniases of the New-World - Current Concepts and Implications for Future Research". ...

*Leishmania donovani

It is a human blood parasite responsible for visceral leishmaniasis or kala-azar, the most severe form of leishmaniasis. It ... at Centers for Disease Control and Prevention Brief account Transmission of visceral leishmaniasis Visceral leishmaniasis at ... This was the first time an oral drug is effective for visceral leishmaniasis. Clinical trials showed that the new drug is ... Mahajan R.C.; Mohan K. (1996). "Epidemiology of visceral leishmaniasis and its control". In M. Ziya Alkan; M. Ali Özcel. ...

*Neglected tropical disease research and development

Drug resistance in visceral leishmaniasis. J Biomed Biotechnol 2010;2010:617521. Mathers CD, Ezzati M, Lopez AD. Measuring the ... sleeping sickness and visceral leishmaniasis. Ann Trop Med Parasitol 2010 Oct;104(7):535-542. Bottazzi ME, Brown AS. Model for ... Ameen M. Cutaneous leishmaniasis: therapeutic strategies and future directions. Expert Opin Pharmacother 2007 Nov;8(16):2689- ... These seven are among a larger list of thirteen major NTDs: onchocerciasis, leishmaniasis, Chagas' disease, leprosy, Human ...

*Amphotericin B

... is often used in otherwise-untreatable protozoan infections such as visceral leishmaniasis and primary amoebic ... 2011 den Boer, Margriet; Davidson, Robert N. (2006-04-01). "Treatment options for visceral leishmaniasis". Expert Review of ... 2009). "Highly Effective oral amphotericin B formulation against murine visceral leishmaniasis". J Infect Dis. 200 (3): 357-360 ... Control of the leishmaniasis: report of a meeting of the WHO Expert Committee on the Control of Leishmaniases (PDF). World ...

*Domestication of the Syrian hamster

"Kala Azar" is visceral leishmaniasis. Adler, S.; Theodor, O. (1931). "Investigations on Mediterranean Kala Azar. I.-- ... Leishmaniasis was a regional problem and it was common to infect Chinese hamsters as a model organism to study the disease. ...

*Paromomycin

"Injectable paromomycin for visceral leishmaniasis in India". N. Engl. J. Med. 356 (25): 2571-81. doi:10.1056/NEJMoa066536. PMID ... and in trials with visceral leishmaniasis in the early 1990s. The route of administration is intramuscular injection and ... and other diseases such as leishmaniasis. Paromomycin was demonstrated to be effective against cutaneous leishmaniasis in ... Paromomycin is an antibiotic used to treat a number of infections including amebiasis, giardiasis, leishmaniasis, and tapeworm ...

*List of vaccine topics

Nakkazi, E. (March 12, 2012). "New vaccine trials to prevent visceral leishmaniasis". New Science Journalism. Retrieved June 16 ... vaccine Hookworm vaccine Onchocerciasis river blindness vaccine for humans Trypanosomiasis vaccine Visceral leishmaniasis ...

*Miltefosine

This includes leishmaniasis of the cutaneous, visceral, and mucosal types. It may be used together with liposomal amphotericin ... 2014). "Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia". PLoS ONE. 9 (6): ... Miltefosine is primarily used for the treatment of visceral and New World cutaneous leishmaniasis, and is undergoing clinical ... launches Impavido® (miltefosine), the first and only oral Rx treatment for visceral, mucosal and cutaneous leishmaniasis, in ...

*Macrophage

Goto, H (2009). "Immunoactivation and immunopathogeny during active visceral leishmaniasis". Rev Inst Med Trop Sao Paulo. 51: ... Diseases with this type of behaviour include tuberculosis (caused by Mycobacterium tuberculosis) and leishmaniasis (caused by ...

*Latex fixation test

Visceral leishmaniasis#Diagnosis Howanitz and Howanitz, Laboratory Medicine. Published by Church Livingston; 1991: pp 825-828 ...

*Leishmaniasis

The visceral form of leishmaniasis has an estimated incidence of 500,000 new cases. More than 90% of the world's cases of ... Leishmaniasis at Curlie (based on DMOZ) Doctors Without Borders' Leishmaniasis Information Page CDC Leishmaniasis Page Medicine ... Visceral leishmaniasis or kala-azar ('black fever') is the most serious form, and is potentially fatal if untreated. Other ... Additionally, visceral disease can be diagnosed by blood tests. Leishmaniasis can be partly prevented by sleeping under nets ...

*Pentamidine

It is an option for both visceral leishmaniasis and cutaneous leishmaniasis. Pentamidine can be given by injection into a vein ... Pentamidine was first used to treat African trypanosomiasis in 1937 and leishmaniasis in 1940 before it was registered as ... Pentamidine is an antimicrobial medication used to treat African trypanosomiasis, leishmaniasis, babesiosis, and to prevent and ... 200mm³ Treatment of leishmaniasis Treatment of African trypanosomiasis caused by Trypanosoma brucei gambiense Pentamidine is ...

*Egyptian mongoose

It may be a reservoir host for visceral leishmaniasis in Sudan. This mongoose can be found in Egypt, Morocco, Libya, Spain, ... is a possible reservoir host of visceral leishmaniasis in eastern Sudan". Retrieved 2007-04-17. Detry, Cleia; Bicho, Nuno; ...

*Fexinidazole

"The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis". Science Translational Medicine. 4 ...

*Health in Afghanistan

Visceral leishmaniasis infections are often recognised by fever, swelling of the liver and spleen, and anemia. They are known ... Two Cases of Visceral Leishmaniasis in U.S. Military Personnel "Health". United States Agency for International Development ( ...

*Alan Fairlamb

"The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis". Sci. Transl. Med. 4: 119re1. doi: ... on trypanothione metabolism resulted in the discovery that fexinidzole is a potential oral treatment for visceral leishmaniasis ... Chagas disease and leishmaniasis. He was one of the 250 scientists involved in the genome sequencing of these parasites. In ...

*Rajendra Memorial Research Institute of Medical Sciences

Its main thrust is research in different aspects of visceral leishmaniasis. It is named after the memory of the first president ...

*Dichlorodiphenyltrichloroethane

In 2009, 3,314 tonnes were produced for malaria control and visceral leishmaniasis. India is the only country still ...

*Neglected tropical diseases

It is fatal if untreated and 20,000 deaths from visceral leishmaniasis occur annually. It is a vector-borne disease that is ... The three forms of leishmaniasis are visceral (Kala-azar), cutaneous, and mucocutaneous. There are an estimated 12 million ... At least 90 percent of visceral leishmaniasis occurs in Bangladesh, Brazil, Ethiopia, India, South Sudan, and Sudan. Cutaneous ... and visceral leishmaniasis. Migration paths to Europe, most notably to Spain, have brought diseases to Europe as well. As many ...

*London Declaration on Neglected Tropical Diseases

... visceral leishmaniasis and river blindness. The original endorsers with their basic strategies were: Abbott: A US-based global ... for treatment of visceral leishmaniasis. GlaxoSmithKline: A London-based multinational pharmaceutical and consumer healthcare ...

*Regulatory T cell

CD8+ T suppressor cells predominate in patients with no protective immunity (visceral leishmaniasis patients). When added to ... Holaday BJ (1999). "Immunotherapy for visceral leishmaniasis: ability of factors produced during anti-leishmania responses of ... skin test positive adults to inhibit peripheral blood mononuclear cell activities associated with visceral leishmaniasis". Mem ... and kill CD8+ T suppressor cells might be useful in treating diseases that involve immune suppression such as leishmaniasis, ...

*Mohan Mishra

Mishra's studies on Visceral leishmaniasis are considered by many as his most notable contribution. Leishmaniasis, the second ... Mohan Mishra is an Indian physician, known for his studies on Visceral leishmaniasis, (Kala Azar) and its treatment using ... India portal Leishmaniasis Amphotericin B "India Medical Times". India Medical Times. 2014. Retrieved November 5, 2014. "News ... "Leishmaniasis". WHO. 2014. Retrieved November 5, 2014. Mohan Mishra, Narottam Mishra (2012). India Through Alien Eyes. Balboa ...

*Simple Explanation

House realizes Charlotte was in Rio without telling Eddie, where she contracted visceral leishmaniasis. The team starts her on ...

*Direct agglutination test

The abbreviation, DAT, is most frequently used for the serological test for visceral leishmaniasis. Sundar S, Singh RK, Maurya ... 2006). "Serological diagnosis of Indian visceral leishmaniasis: direct agglutination test versus rK39 strip test". Trans R Soc ...

*Post-kala-azar dermal leishmaniasis

... after the successful treatment of visceral leishmaniasis List of cutaneous conditions Rapini, Ronald P.; Bolognia, Jean L.; ... ISBN 0-7216-2921-0. Zijlstra EE; Musa AM; Khalil EAG; el-Hassan IM; el-Hassan AM (2003). "Post-kala-azar dermal leishmaniasis ... Post-kala-azar dermal leishmaniasis (also known as "Post-kala-azar dermatosis") is a cutaneous condition that is characterized ...

*Infectious Disease Research Institute

On February 2012, IDRI launched the world's first clinical trial of the visceral leishmaniasis vaccine. The vaccine is a ...